Table 2.
Comparison of characteristics among patients receiving three different initial bolus heparin dosages for each non-vitamin K antagonist oral anticoagulant
| Dabigatran | Rivaroxaban | Apixaban | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolus heparin dosage: | 110 U/kg | 120 U/kg | 130 U/kg | P value | 110 U/kg | 120 U/kg | 130 U/kg | P value | 110 U/kg | 120 U/kg | 130 U/kg | P value |
| Number of patients | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | |||
| Age (years) | 63 ± 10 | 64 ± 8 | 63 ± 10 | 0.98 | 61 ± 12 | 62 ± 9 | 64 ± 10 | 0.34 | 65 ± 11 | 63 ± 10 | 66 ± 11 | 0.77 |
| Sex, female, N (%) | 9 (30 %) | 7 (23 %) | 8 (27 %) | 0.85 | 7 (23 %) | 5 (17 %) | 3 (10 %) | 0.57 | 6 (20 %) | 6 (20 %) | 12 (40 %) | 0.13 |
| Type of AF | ||||||||||||
| Paroxysmal, N (%) | 18 (60 %) | 17 (57 %) | 19 (63 %) | 0.98 | 18 (60 %) | 19 (63 %) | 19 (63 %) | 0.94 | 21 (70 %) | 22 (73 %) | 19 (63 %) | 0.41 |
| Persistent, N (%) | 8 (27 %) | 7 (23 %) | 7 (23 %) | 9 (30 %) | 10 (33 %) | 9 (30 %) | 6 (20 %) | 5 (17 %) | 10 (33 %) | |||
| Long-standing persistent, N (%) | 4 (13 %) | 6 (20 %) | 4 (14 %) | 3 (10 %) | 1 (4 %) | 2 (7 %) | 3 (10 %) | 3 (10 %) | 1 (4 %) | |||
| Duration of AF (years) | 8 ± 12 | 5 ± 4 | 4 ± 4 | 0.36 | 4 ± 2 | 3 ± 2 | 4 ± 4 | 0.97 | 5 ± 4 | 4 ± 3 | 3 ± 2 | 0.42 |
| Echocardiography parameters | ||||||||||||
| LVEF (%) | 66 ± 6 | 65 ± 11 | 65 ± 10 | 0.99 | 65 ± 7 | 65 ± 6 | 66 ± 9 | 0.80 | 65 ± 9 | 67 ± 7 | 64 ± 7 | 0.13 |
| LA diameter (mm) | 41 ± 6 | 41 ± 7 | 41 ± 7 | 0.98 | 41 ± 5 | 41 ± 5 | 40 ± 6 | 0.99 | 42 ± 5 | 42 ± 4 | 41 ± 5 | 0.64 |
| CHADS2 score | 0.4 ± 0.6 | 0.5 ± 0.6 | 0.7 ± 0.8 | 0.54 | 0.5 ± 0.7 | 0.7 ± 0.8 | 0.4 ± 0.6 | 0.36 | 0.6 ± 0.8 | 0.4 ± 0.7 | 0.6 ± 0.7 | 0.71 |
| 0 | 19 (63 %) | 17 (57 %) | 16 (53 %) | 0.29 | 17 (57 %) | 15 (50 %) | 19 (63 %) | 0.89 | 18 (60 %) | 20 (67 %) | 17 (57 %) | 0.82 |
| 1 | 9 (30 %) | 11 (36 %) | 8 (27 %) | 10 (33 %) | 8 (27 %) | 9 (30 %) | 7 (23 %) | 7 (23 %) | 9 (30 %) | |||
| ≥2 | 2 (7 %) | 2 (7 %) | 6 (20 %) | 3 (10 %) | 7 (23 %) | 2 (7 %) | 5 (17 %) | 3 (10 %) | 4 (13 %) | |||
| CHA2DS2-VASc score | 1.3 ± 1.3 | 1.4 ± 1.3 | 1.6 ± 1.5 | 0.77 | 1.2 ± 1.2 | 1.5 ± 1.3 | 1.2 ± 1.1 | 0.64 | 1.6 ± 0.9 | 1.5 ± 0.9 | 1.7 ± 1.1 | 0.75 |
| Cr (mg/dL) | 0.83 ± 0.23 | 0.84 ± 0.19 | 0.76 ± 0.15 | 0.23 | 0.85 ± 0.23 | 0.83 ± 0.21 | 0.88 ± 0.15 | 0.32 | 0.89 ± 0.24 | 0.89 ± 0.18 | 0.82 ± 0.22 | 0.18 |
| CCr (mL/min) | 87 ± 26 | 87 ± 16 | 88 ± 20 | 0.66 | 97 ± 42 | 94 ± 33 | 79 ± 17 | 0.14 | 79 ± 27 | 82 ± 22 | 79 ± 20 | 0.81 |
Values are presented as mean ± standard deviation
AF atrial fibrillation, CCr creatinine clearance, Cr creatinine, LA left atrium, LVEF left ventricular ejection fraction